Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Associations of cerebrospinal fluid measures of synaptic function with white matter microstructure and cognition in older adults.

Frontiers in aging neuroscience·2026
Same author

Plasma GDF15 affects long-term dementia risk and alters neuroimmune signaling.

Science advances·2026
Same author

Five-year change in brain metabolism across the spectrum of cognitive impairment in older adults: a quantitative MRI study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Uncovering lipid biomarkers linked to methylphenidate efficacy in treating apathy in Alzheimer's disease: insights from the ADMET 2 trial.

Alzheimer's research & therapy·2026
Same author

Disproportionately elevated sulcal index (DESI): An automatically driven index representing disproportionate subarachnoid space enlargement in brain MRI scans.

Brain research bulletin·2026
Same author

Plasma inflammatory markers and brain white matter microstructure in late middle-aged and older adults.

medRxiv : the preprint server for health sciences·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Maansi Barnwal1, Sheriza Baksh2, David Shade1

  • 1Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

埃斯基塔洛普拉姆并没有改善阿尔茨海默病 (AD) 患者的激动. 较高的基线pTau217血液生物标志物水平预测了更糟糕的激动和较低的认知分数,无论治疗方式如何.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 生物标志物 生物标志物
  • 临床试验 临床试验

背景情况:

  • 阿尔茨海默病 (AD) 和动荡是患者护理中的重大挑战.
  • 在S-CitAD试验中,研究了埃斯基塔洛普拉姆对阿尔茨海默病的激发作用,但没有显示出显著的益处.
  • 阿尔茨海默病症病理阶段的变化可能解释了治疗效率的缺乏.

研究的目的:

  • 为了研究基线血液生物标志物与动荡严重程度,认知状态和阿尔茨海默病患者治疗反应之间的关联.
  • 探索像pTau217,GFAP,NfL,Abeta40和Abeta42这样的生物标志物在预测激动和认知衰退中的作用.

主要方法:

  • 检查了基线血液生物标志物 (pTau217,GFAP,NfL,Abeta40,Abeta42) 和临床措施 (激发,MMSE) 之间的关联.
  • 使用SIMOA N4PE试验和Alzpath-pTau217SIMOA在Quanterix HD-X上进行生物标志物定量.
  • 分析了S-CitAD随机对照试验中的173名参与者的数据.

主要成果:

  • 基线pTau217水平在94%的参与者中证实了显著的粉样蛋白病理.
  • 较高的基线pTau217预测在第6周和第12周激发严重程度增加.
  • 较高的基线GFAP和pTau217水平与较低的基线MMSE得分相关.

结论:

  • 基线pTau217是AD粉样蛋白病理学的可靠指标.
  • 升高的pTau217预测AD患者的认知功能较差和兴奋程度增加.
  • 生物标志物水平,特别是pTau217,对于了解阿尔茨海默病患者的治疗反应和疾病进展至关重要.